Prothena Corp. (PRTA) Misses Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Prothena Corp. (PRTA) Misses Q2 EPS by 7c

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

August 3, 2023 4:05 PM EDT

Net cash used in operating and investing activities was $45.7 million in the second quarter and $93.2 million for the first six months of 2023; quarter-end cash and restricted cash position was $661.3 million Revised year-end cash guidance to be approximately $600 million in cash, cash equivalents and restricted cash, representing an increase of $88 million from prior guidance of $512 million Presented research across multiple Alzheimers disease programs targeting amyloid-beta and tau at AAIC 2023, including data on PRX012, PRX005 and PRX123 Bristol Myers Squibb (BMS) obtained the $55 million exclusive worldwide license to PRX005 in July, expanding on the... More